RxDoctor Payments Data

Richard Tepper, MD

Infectious Disease · Southampton, PANPI 1588639165

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 62 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$287
  • Johnson & Johnson$239
  • Gilead$180
  • Merck$167
  • AbbVie$120
  • Paratek Pharmaceuticals, Inc.$96
  • plus $243 from 7 others

What the payments were for

  • Speaking & faculty fees$212%
  • Food & beverage$1,23393%
  • Education$786%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,332 in reported general payments places this provider in the 70th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$156,684
Medicare patients
579
Services billed
3,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala58$225,156
TriumeqAbacavir/Dolutegravir/Lamivudi56$208,438
NuzyraOmadacycline Tosylate13$178,155
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$78,275
DescovyEmtricitabine/Tenofov Alafenam13$27,778
Daptomycin18$25,971
AbacavirAbacavir Sulfate11$2,623
CeftriaxoneCeftriaxone Sodium12$1,457
Vancomycin Hcl15$1,434
Ethambutol Hcl28$1,196
Doxycycline Hyclate33$987
Azithromycin43$725
Rifampin15$715
Gabapentin21$490
Ciprofloxacin Hcl20$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$180$331,20884 claims
Viiv Healthcare CompanyTriumeq$68$208,43856 claims
Paratek Pharmaceuticals, Inc.Nuzyra$96$178,15513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 457 infectious disease providers in Pennsylvania.

Other infectious disease in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →